A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase II/III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary) ; Ustekinumab; Ustekinumab
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms GALAXI; GALAXI 1; GALAXI 2; GALAXI 3
- Sponsors Janssen Pharmaceuticals; Janssen Research & Development; Janssen-Cilag
- 22 Nov 2019 Planned End Date changed from 23 Oct 2024 to 3 Apr 2026.
- 01 Nov 2019 This trial has been suspended in Germany and Portugal, according to European Clinical Trials Database record.
- 21 Feb 2019 Planned End Date changed from 1 Feb 2025 to 23 Oct 2024.